Angiopoietin-1 (Ang-1) is essential for the maturation of blood vessels during vasculogenesis. Besides angiogenesis, recent publications indicate that Ang-1 is also a potent survival factor for endothelial cells; however, the mechanisms by which pathways remain elusive. Doxorubicin (DOX) is a powerful anticancer drug, but its use is severely restricted by its cardiotoxicity. The authors report here that Ang-1 inhibits DOX-induced cell death in human umbilical vein endothelial cells (HUVECs). Interestingly, the DOX-induced up-regulation in Fas (CD95/APO-1) and Fas ligand expression could be blocked by Ang-1, indicating a pivotal role of Ang-1 in DOX-induced Fas and Fas ligand expression. In addition, the prevention of cell death in this model system seems to be dependent on the activation of phosphatidylinositol 3-kinase (PI3K)/Akt, as Ang-1 fails to inhibit DOX-induced cell death while PI3K/Akt pathway was blocked by the PI3K inhibitor LY294002. Moreover, Ang-1 inhibits DOX-induced up-regulation of p53 through PI3K/Akt. Therefore, Ang-1 is a potent inhibitor for DOX-induced cell death through Fas and PI3K/Akt-mediated pathways.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10623320490904115DOI Listing

Publication Analysis

Top Keywords

cell death
20
dox-induced cell
12
human umbilical
8
umbilical vein
8
vein endothelial
8
pi3k/akt pathway
8
ang-1
8
ang-1 potent
8
endothelial cells
8
ang-1 inhibits
8

Similar Publications

Immune infiltration plays a significant role in the pathogenesis of rheumatoid arthritis (RA). Cuproptosis, a newly characterized form of programmed cell death, remains insufficiently investigated regarding its genetic regulation of immune infiltration in RA. Data from the GEO database were analyzed to determine the relationship between cuproptosis-related genes and immune infiltration.

View Article and Find Full Text PDF

New insights into constitutive neutrophil death.

Cell Death Discov

January 2025

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, CAMS Key laboratory for prevention and control of hematological disease treatment related infection, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, 300020, China.

Neutrophils undergo rapid aging and death known as constitutive or spontaneous death. Constitutive neutrophil death (CND) contributes to neutrophil homeostasis and inflammation resolution. CND has long been considered to be apoptotic until our findings reveal that it was a heterogeneous combination of diverse death.

View Article and Find Full Text PDF

Developing novel Lin28 inhibitors by computer aided drug design.

Cell Death Discov

January 2025

The Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, 2660 Oak Street, Vancouver, BC, V6H 3Z6, Canada.

Lin28 is a key regulator of cancer stem cell gene network that promotes therapy-resistant tumor progression in various tumors. However, no Lin28 inhibitor has been approved to treat cancer patients, urging exploration of novel compounds as candidates to be tested for clinical trials. In this contribution, we applied computer-aided drug design (CADD) in combination with quantitative biochemical and biological assays.

View Article and Find Full Text PDF

DNA methylation of ACADS promotes immunogenic cell death in hepatocellular carcinoma.

Cell Biosci

January 2025

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China.

Background: Altered metabolism has become an important characteristic of cancer, and acyl-CoA dehydrogenase short-chain (ACADS), a regulator of lipid synthesis, is involved in carcinogenesis-associated metabolic pathways. DNA methylation is an important mechanism for silencing ACADS in various malignancies. However, the specific role of ACADS in hepatocellular carcinoma (HCC) pathogenesis remains poorly understood.

View Article and Find Full Text PDF

This is a randomized, double-blind, placebo-controlled phase 3 clinical trial (ClinicalTrials.gov, NCT04878016) conducted in 54 hospitals in China. Adults who were histologically diagnosed and never treated for extensive-stage small cell lung cancer (ES-SCLC) were enrolled.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!